FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jonas Oldgren

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Hein Heidbuchel; Jonas Oldgren; Peter Sinnaeve; Peter Verhamme; Marco Alings; Matthias Antz; A John Camm; Werner Hacke; Paulus Kirchhof
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
Ziad Hijazi; Jonas Oldgren; Agneta Siegbahn; Christopher B Granger; Lars Wallentin
Biomarkers in atrial fibrillation: a clinical review.
Guillaume Paré; Paul Reilly; Agneta Siegbahn; Ann-Christine Syvanen; Claes Wadelius; Mia Wadelius; Salim Yusuf; Heike Zimdahl-Gelling; Tomas Axelsson; Stuart Connolly; John Eikelboom; Niclas Eriksson; Michael D Ezekowitz; Sebastian Haertter; Thorsten Lehr; Jonas Oldgren; Lars Wallentin
Genetic determinants of dabigatran plasma levels and their relation to bleeding.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jonas Oldgren (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Hein Heidbuchel; Jonas Oldgren; Peter Sinnaeve; Peter Verhamme; Marco Alings; Matthias Antz; A John Camm; Werner Hacke; Paulus Kirchhof
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2013;15(5):625-51.
2013: Ziad Hijazi; Jonas Oldgren; Agneta Siegbahn; Christopher B Granger; Lars Wallentin
Biomarkers in atrial fibrillation: a clinical review.
European heart journal 2013;34(20):1475-80.
2013: Guillaume Paré; Paul Reilly; Agneta Siegbahn; Ann-Christine Syvanen; Claes Wadelius; Mia Wadelius; Salim Yusuf; Heike Zimdahl-Gelling; Tomas Axelsson; Stuart Connolly; John Eikelboom; Niclas Eriksson; Michael D Ezekowitz; Sebastian Haertter; Thorsten Lehr; Jonas Oldgren; Lars Wallentin
Genetic determinants of dabigatran plasma levels and their relation to bleeding.
Circulation 2013;127(13):1404-12.
2013: Jeff S Healey; Hein Heidbuchel; Jonas Oldgren; Paul Reilly; Ellison Themeles; Lars Wallentin; Sean Yang; Salim Yusuf; Alvaro Avezum; Stuart J Connolly; James Douketis; John Eikelboom; Michael Ezekowitz
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.
Circulation 2013;127(11):e506.
2013: Antonio L Dans; John W Eikelboom; Michael Ezekowitz; Juliet Nakamya; Jonas Oldgren; Paul A Reilly; Lars Wallentin; Sean Yang; Martina Brueckmann; Stuart J Connolly; Salim Yusuf
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Circulation 2013;127(5):634-40.
2013: Ziad Hijazi; Stefan H Hohnloser; Jonas Oldgren; Paul A Reilly; Ulrika Andersson; Stuart J Connolly; Michael D Ezekowitz; Dragos Vinereanu; Lars Wallentin; Salim Yusuf; Agneta Siegbahn
Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy".
Circulation 2013;127(2):e278-9.
2013: Thomas Davidson; M Husberg; Magnus Janzon; Jonas Oldgren; Lars-Åke Levin
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
European heart journal 2013;34(3):177-83.
2012: Jeff S Healey; Hein Heidbuchle; Jonas Oldgren; Paul Reilly; Ellison Themeles; Lars Wallentin; Sean Yang; Salim Yusuf; Hein Heidbuchel; Alvaro Avezum; Stuart J Connolly; James Douketis; John Eikelboom; Michael Ezekowitz
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Circulation 2012;126(3):343-8.
2012: Ziad Hijazi; Stefan H Hohnloser; Jonas Oldgren; Paul A Reilly; Agneta Siegbahn; Dragos Vinereanu; Ulrika Andersson; Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; Lars Wallentin
Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.
Circulation 2012;125(13):1605-16.
2012: Stefan H Hohnloser; Jonas Oldgren; Paul Reilly; Lars Wallentin; Sean Yang; Salim Yusuf; Martina Brueckmann; John Eikelboom; Michael Ezekowitz; Stuart J Connolly
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Circulation 2012;125(5):669-76.
2011: C Christersson; Jonas Oldgren; L Wallentin; A Siegbahn
Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction.
Journal of internal medicine 2011;270(3):215-23.
2011: John W Eikelboom; Lars Wallentin; Stuart J Connolly; Mike Ezekowitz; Jeff S Healey; Jonas Oldgren; Sean Yang; Marco Alings; Scott Kaatz; Stefan H Hohnloser; Hans-Christoph Diener; Maria Grazia Franzosi; Kurt Huber; Paul Reilly; Jeanne Varrone; Salim Yusuf
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Circulation 2011;123(21):2363-72.
2011: Rangadham Nagarakanti; Michael D Ezekowitz; Jonas Oldgren; Sean Yang; Michael Chernick; Timothy H Aikens; Greg Flaker; Josep Brugada; Gabriel Kamensky; Amit Parekh; Paul A Reilly; Salim Yusuf; Stuart J Connolly
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Circulation 2011;123(2):131-6.
2010: Michael Koutouzis; Bo Lagerqvist; Jonas Oldgren; Axel Akerblom; Magnus Wahlin; Thomas Karlsson; Per Albertsson; Göran Matejka; Lars Grip
Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention.
Clinical cardiology 2010;33(11):686-92.
2010: Lars Wallentin; Salim Yusuf; Michael D Ezekowitz; Marco Alings; Marcus Flather; Maria Grazia Franzosi; Prem Pais; Antonio Dans; John Eikelboom; Jonas Oldgren; Janice Pogue; Paul A Reilly; Sean Yang; Stuart J Connolly
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
Lancet 2010;376(9745):975-83.
2010: Jonas Oldgren; Lisa Wernroth; Ulf Stenestrand
Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA.
Heart (British Cardiac Society) 2010;96(18):1451-7.
2010: Axel Akerblom; Stefan K James; Michail Koutouzis; Bo Lagerqvist; Ulf Stenestrand; Bodil Svennblad; Jonas Oldgren
Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
Journal of the American College of Cardiology 2010;56(6):470-5.
2010: Kai M Eggers; Mikael Dellborg; Nina Johnston; Jonas Oldgren; Eva Swahn; Per Venge; Bertil Lindahl
Myeloperoxidase is not useful for the early assessment of patients with chest pain.
Clinical biochemistry 2010;43(3):240-5.
2009: Jonas Oldgren
[Still strong reason for enthusiasm for a new stroke-preventing drug].
Läkartidningen 2009;106(45):3020-1.
2009: Ulrica Alström; Fredrik Granath; Jonas Oldgren; Elisabeth Ståhle; H Tydén; Agneta Siegbahn
Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery.
Thrombosis research 2009;124(5):572-7.
2009: Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S. Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Dabigatran versus warfarin in patients with atrial fibrillation.
The New England journal of medicine 2009;361(12):1139-51.
2009: Michael D Ezekowitz; Stuart Connolly; Amit Parekh; Paul A Reilly; Jeanne Varrone; Susan Wang; Jonas Oldgren; Ellison Themeles; Lars Wallentin; Salim Yusuf
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
American heart journal 2009;157(5):805-10, 810.e1-2.
2008: Kai M Eggers; Bo Lagerqvist; Jonas Oldgren; Per Venge; Lars Wallentin; Bertil Lindahl
Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome.
American heart journal 2008;156(3):588-94.
2008: Kai M Eggers; Mikael Dellborg; Jonas Oldgren; Eva Swahn; Per Venge; Bertil Lindahl
Risk prediction in chest pain patients by biochemical markers including estimates of renal function.
International journal of cardiology 2008;128(2):207-13.
2008: Jonas Oldgren; Nina Johnston; Agneta Siegbahn
Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
American heart journal 2008;155(3):493.e1-8.
2008: Ron J G Peters; Campbell Joyner; Jean-Pierre Bassand; Rizwan Afzal; Susan Chrolavicius; Shamir R Mehta; Jonas Oldgren; Lars Wallentin; Andrzej Budaj; Keith A A Fox; Salim Yusuf
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial.
European heart journal 2008;29(3):324-31.
2008: Marco J D Tangelder; Lars Frison; Douglas Weaver; Robert G Wilcox; Anders Bylock; Håkan Emanuelsson; Peter Held; Jonas Oldgren
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
American heart journal 2008;155(2):382-7.
2008: Jonas Oldgren; Lars Wallentin; Rizwan Afzal; Jean-Pierre Bassand; Andrzej Budaj; Susan Chrolavicius; Keith A A Fox; Christopher B Granger; Shamir R Mehta; Prem Pais; Ron J G Peters; Denis Xavier; Jun Zhu; Salim Yusuf
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment.
European heart journal 2008;29(3):315-23.
2007: Christina Christersson; Jonas Oldgren; Anders Bylock; Agneta Siegbahn; Lars Wallentin
Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.
European heart journal 2007;28(6):692-8.
2007: Jonas Oldgren; Stefan K James; Agneta Siegbahn; Lars Wallentin
Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.
European heart journal 2007;28(6):699-704.
2007: Kai M Eggers; Johan Ellenius; Mikael Dellborg; Torgny Groth; Jonas Oldgren; Eva Swahn; Bertil Lindahl
Artificial neural network algorithms for early diagnosis of acute myocardial infarction and prediction of infarct size in chest pain patients.
International journal of cardiology 2007;114(3):366-74.
2007: Ulrica Alström; Hans Tydén; Jonas Oldgren; Agneta Siegbahn; Elisabeth Ståhle
The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment.
Thrombosis research 2007;120(3):353-9.
2005: Jonas Oldgren; C Fellenius; K Boman; Jan-Håkan Jansson; Tage Nilsson; Lars Wallentin; Agneta Siegbahn
Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.
Journal of internal medicine 2005;258(5):420-7.
2005: C Christersson; Jonas Oldgren; Anders Bylock; Lars Wallentin; Agneta Siegbahn
Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
Journal of thrombosis and haemostasis : JTH 2005;3(10):2245-53.
2005: Kai M Eggers; Jonas Oldgren; Anna Nordenskjöld; Bertil Lindahl
Combining different biochemical markers of myocardial ischemia does not improve risk stratification in chest pain patients compared to troponin I alone.
Coronary artery disease 2005;16(5):315-9.
2005: Kai M Eggers; Jonas Oldgren; Anna Nordenskjöld; Bertil Lindahl
Risk prediction in patients with chest pain: early assessment by the combination of troponin I results and electrocardiographic findings.
Coronary artery disease 2005;16(3):181-9.
2005: Stefan K James; Jonas Oldgren; Johan Lindbäck; Nina Johnston; Agneta Siegbahn; Lars Wallentin
An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease.
American heart journal 2005;149(4):619-26.
2004: Kai M Eggers; Jonas Oldgren; Anna Nordenskjöld; Bertil Lindahl
Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction.
American heart journal 2004;148(4):574-81.
2004: Jakob Johansson; R Hammerby; Jonas Oldgren; Sten Rubertsson; Rolf Gedeborg
Adrenaline administration during cardiopulmonary resuscitation: poor adherence to clinical guidelines.
Acta anaesthesiologica Scandinavica 2004;48(7):909-13.
2004: Jonas Oldgren; Agneta Siegbahn; Lars Grip; Rikard Linder; Kristian Thygesen; Lars Wallentin
Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
Thrombosis and haemostasis 2004;91(2):381-7.
2003: Jonas Oldgren; Lars Wallentin; Lars Grip; Rikard Linder; Bjarne Linde Nørgaard; Agneta Siegbahn
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease.
European heart journal 2003;24(1):86-93.
2001: Jonas Oldgren; Rikard Linder; Lars Grip; Agneta Siegbahn; Lars Wallentin
Coagulation activity and clinical outcome in unstable coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(6):1059-64.
1999: Jonas Oldgren; Rikard Linder; Lars Grip; Agneta Siegbahn; Lars Wallentin
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
European heart journal 1999;20(22):1657-66.
1999: Rikard Linder; Jonas Oldgren; Nils Egberg; Lars Grip; G Larson; Agneta Siegbahn; Lars Wallentin
The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
European heart journal 1999;20(7):506-18.